Advertisement

Neuromyelitis optica: Effect of gender

Published:September 09, 2009DOI:https://doi.org/10.1016/j.jns.2009.08.045

      Abstract

      Neuromyelitis optica is a distinct CNS demyelinating disease associated with the autoantibody NMO-IgG, which targets the water channel aquaporin-4. Neuromyelitis optica may be distinguished from typical multiple sclerosis on the basis of key clinical and neuroimaging characteristics in addition to detection of NMO-IgG. The disease has an even stronger female predilection than does multiple sclerosis, with a reasonably consistent female to male gender ratio of >3:1 reported from samples of diverse racial and regional populations worldwide. The gender distribution appears to be similar in both childhood-onset and adult-onset cases. Female gender is associated with a relapsing course and familial disease, but the influence of gender on disease severity and treatment response are not clear. Population-based epidemiological and genetic studies, with case ascertainment aided by the high specificity of NMO-IgG and consistent disease definitions, are needed to better define and understand gender effects in neuromyelitis optica.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wingerchuk D.M.
        • Lennon V.A.
        • Lucchinetti C.F.
        • Pittock S.J.
        • Weinshenker B.G.
        The spectrum of neuromyelitis optica.
        Lancet Neurol. 2007; 6: 805-815
        • Devic E.
        Myelite subaigue compliquee de neurite optique.
        Bull Med. 1894; 8: 1033-1034
        • Gault F.
        De la neuromyelite optique ague (thesis).
        Lyon, France: University of Lyon. 1894;
        • Stansbury F.C.
        Neuromyelitis optica; presentation of five cases, with pathologic study, and review of literature.
        Arch Ophthalmol. 1949; 42: 292
        • O'Riordan J.I.
        • Gallagher H.L.
        • Thompson A.J.
        • et al.
        Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.
        J Neurol Neurosurg Psychiatry. 1996; 60: 382-387
        • Wingerchuk D.M.
        • Hogancamp W.F.
        • O'Brien P.C.
        • Weinshenker B.G.
        The clinical course of neuromyelitis optica (Devic's syndrome).
        Neurology. 1999; 53: 1107-1114
        • Mandler R.N.
        • Davis L.E.
        • Jeffery D.R.
        • Kornfeld M.
        Devic's neuromyelitis optica: a clinicopathological study of 8 patients.
        Ann Neurol. 1993; 34: 162-168
        • Lefkowitz D.
        • Angelo J.N.
        Neuromyelitis optica with unusual vascular changes.
        Arch Neurol. 1984; 41: 1103-1105
        • de Seze J.
        Neuromyelitis optica.
        Arch Neurol. 2003; 60: 1336-1338
        • Lennon V.A.
        • Wingerchuk D.M.
        • Kryzer T.J.
        • et al.
        A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
        Lancet. 2004; 364: 2106-2112
        • Wingerchuk D.M.
        • Lennon V.A.
        • Pittock S.J.
        • Lucchinetti C.F.
        • Weinshenker B.G.
        Revised diagnostic criteria for neuromyelitis optica.
        Neurology. 2006; 66: 1485-1489
        • Lennon V.A.
        • Kryzer T.J.
        • Pittock S.J.
        • Verkman A.S.
        • Hinson S.R.
        IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.
        J Exp Med. 2005; 202: 473-477
        • Takahashi T.
        • Fujihara K.
        • Nakashima I.
        • et al.
        Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.
        Tohoku J Exp Med. 2006; 210: 307-313
        • Jarius S.
        • Franciotta D.
        • Bergamaschi R.
        • et al.
        NMO-IgG in the diagnosis of neuromyelitis optica.
        Neurology. 2007; 68: 1076-1077
        • Matsuoka T.
        • Matsushita T.
        • Kawano Y.
        • et al.
        Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.
        Brain. 2007; 130 ([see comment]): 1206-1223
        • Paul F.
        • Jarius S.
        • Aktas O.
        • et al.
        Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
        PLoS Med. 2007; 4: e133
        • Tanaka K.
        • Tani T.
        • Tanaka M.
        • et al.
        Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions.
        Mult Scler. 2007; 13: 850-855
        • Banwell B.
        • Tenembaum S.
        • Lennon V.A.
        • et al.
        Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.
        Neurology. 2008; 70: 344-352
        • Hayakawa S.
        • Mori M.
        • Okuta A.
        • et al.
        Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay.
        J Neuroimmunol. 2008; 196: 181-187
        • Marignier R.
        • De Seze J.
        • Vukusic S.
        • et al.
        NMO-IgG and Devic's neuromyelitis optica: a French experience.
        Mult Scler. 2008; 14: 440-445
        • McKeon A.
        • Lennon V.A.
        • Lotze T.
        • et al.
        CNS aquaporin-4 autoimmunity in children.
        Neurology. 2008; 71: 93-100
        • Misu T.
        • Fujihara K.
        • Nakamura M.
        • et al.
        Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report.
        Tohoku J Exp Med. 2006; 209: 269-275
        • Misu T.
        • Fujihara K.
        • Kakita A.
        • et al.
        Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
        Brain. 2007; 130: 1224-1234
        • Roemer S.F.
        • Parisi J.E.
        • Lennon V.A.
        • et al.
        Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
        Brain. 2007; 130: 1194-1205
        • Takahashi T.
        • Fujihara K.
        • Nakashima I.
        • et al.
        Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
        Brain. 2007; 130: 1235-1243
        • Hinson S.R.
        • Roemer S.F.
        • Lucchinetti C.F.
        • et al.
        Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.
        J Exp Med. 2008; 205: 2473-2481
        • Jarius S.
        • Paul F.
        • Franciotta D.
        • et al.
        Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
        Nat Clin Pract Neurol. 2008; 4: 202-214
        • Vincent T.
        • Saikali P.
        • Cayrol R.
        • et al.
        Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood–brain barrier permeability and granulocyte recruitment.
        J Immunol. 2008; 181: 5730-5737
        • Kira J.
        Multiple sclerosis in the Japanese population.
        Lancet Neurol. 2003; 2: 117-127
        • Waters P.
        • Vincent A.
        Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays.
        Int MS J. 2008; 15: 99-105
        • Jarius S.
        • Aboul-Enein F.
        • Waters P.
        • et al.
        Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
        Brain. 2008; 131: 3072-3080
        • Weinstock-Guttman B.
        • Miller C.
        • Yeh E.
        • et al.
        Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.
        Mult Scler. 2008; 14: 1061-1067
        • Mirsattari S.M.
        • Johnston J.B.
        • McKenna R.
        • et al.
        Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica.
        Neurology. 2001; 56: 317-323
        • Modi G.
        • Mochan A.
        • Modi M.
        • Saffer D.
        Demyelinating disorder of the central nervous system occurring in black South Africans.
        J Neurol Neurosurg Psychiatry. 2001; 70: 500-505
        • Cosnett J.E.
        Multiple sclerosis and neuromyelitis optica. Case report and speculation.
        S Afr Med J. 1981; 60: 249-251
        • Osuntokun B.
        The pattern of neurological illness in tropical Africa. Experience at Ibedan, Nigeria.
        J Neurol Sci. 1971; 12: 417-442
        • Rivera V.M.
        • Cabrera J.A.
        Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica.[comment].
        Neurology. 2001; 57: 937-938
        • Cabre P.
        • Heinzlef O.
        • Merle H.
        • et al.
        MS and neuromyelitis optica in Martinique (French West Indies).
        Neurology. 2001; 56: 507-514
        • Kuroiwa Y.
        • Igata A.
        • Itahara K.
        • Koshijima S.
        • Tsubaki T.
        Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases.
        Neurology. 1975; 25: 845-851
        • Ghezzi A.
        • Bergamaschi R.
        • Martinelli V.
        • et al.
        Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica.
        J Neurol. 2004; 251: 47-52
        • de Seze J.
        • Stojkovic T.
        • Ferriby D.
        • et al.
        Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.
        J Neurol Sci. 2002; 197: 57-61
        • Fardet L.
        • Genereau T.
        • Mikaeloff Y.
        • Fontaine B.
        • Seilhean D.
        • Cabane J.
        Devic's neuromyelitis optica: study of nine cases.
        Acta Neurol Scand. 2003; 108: 193-200
        • Wingerchuk D.M.
        • Pittock S.J.
        • Lucchinetti C.F.
        • Lennon V.A.
        • Weinshenker B.G.
        A secondary progressive clinical course is uncommon in neuromyelitis optica.
        Neurology. 2007; 68: 603-605
        • Rivera J.F.
        • Kurtzke J.F.
        • Booth V.J.
        • Corona V.T.
        Characteristics of Devic's disease (neuromyelitis optica) in Mexico.
        J Neurol. 2008; 255: 710-715
        • Papais-Alvarenga R.M.
        • Miranda-Santos C.M.
        • Puccioni-Sohler M.
        • et al.
        Optic neuromyelitis syndrome in Brazilian patients.
        J Neurol Neurosurg Psychiatry. 2002; 73: 429-435
        • Singhal B.S.
        • Wadia N.H.
        Profile of multiple sclerosis in the Bombay region. On the basis of critical clinical appraisal.
        J Neurol Sci. 1975; 26: 259-270
        • McAlpine D.
        Familial neuromyelitis optica: its occurrence in identical twins.
        Brain. 1938; 61: 430-448
        • Braley T.
        • Mikol D.D.
        Neuromyelitis optica in a mother and daughter.
        Arch Neurol. 2007; 64: 1189-1192
        • Ch'ien L.T.
        • Medeiros M.O.
        • Belluomini J.J.
        • Lemmi H.
        • Whitaker J.N.
        Neuromyelitis optica (Devic's syndrome) in two sisters.
        Clin Electroencephalogr. 1982; 13: 36-39
        • Yamakawa K.
        • Kuroda H.
        • Fujihara K.
        • et al.
        Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan.
        Neurology. 2000; 55: 318-320
        • Cock H.
        • Mandler R.
        • Ahmed W.
        • Schapira A.H.
        Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy.
        J Neurol Neurosurg Psychiatry. 1997; 62: 85-87
        • Kalman B.
        • Mandler R.N.
        Studies of mitochondrial DNA in Devic's disease revealed no pathogenic mutations, but polymorphisms also found in association with multiple sclerosis.
        Ann Neurol. 2002; 51: 661-662
        • Celebisoy N.
        • Akyurekli O.
        • Copur A.
        Devic's neuromyelitis optica: a case with mitochondrial DNA mutations.
        Eur Neurol. 2006; 55: 93-95
        • Ghezzi A.
        • Baldini S.
        • Zaffaroni M.
        • et al.
        Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report.
        Neurol Sci. 2004; 25: S380-S382
        • Hudson G.
        • Mowbray C.
        • Elson J.L.
        • et al.
        Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?.
        Brain. 2008; 131: e93
        • Matiello M.
        • Brum D.G.
        • Barreira A.
        • Kingsbury D.
        • Weinshenker B.
        Familial neuromyelitis optica.
        Neurology. 2008; 70: A266
        • Fukazawa T.
        • Yamasaki K.
        • Ito H.
        • et al.
        Both the HLA-CPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors.
        Tissue Antigens. 2000; 55: 199-205
        • Wingerchuk D.M.
        • Weinshenker B.G.
        Neuromyelitis optica: clinical predictors of a relapsing course and survival.
        Neurology. 2003; 60: 848-853
        • Lotze T.E.
        • Northrop J.L.
        • Hutton G.J.
        • Ross B.
        • Schiffman J.S.
        • Hunter J.V.
        Spectrum of pediatric neuromyelitis optica.
        Pediatrics. 2008; 122: e1039-e1047
        • Aguilera A.J.
        • Carlow T.J.
        • Smith K.J.
        • Simon T.L.
        Lymphocytaplasmapheresis in Devic's syndrome.
        Transfusion. 1985; 25: 54-56
        • Bencherifa F.
        • Bourassi A.
        • Mellal Z.
        • Berraho A.
        Neuromyelite optique de Devic survenue au cours d'une grossesse.
        J Fr Ophtalmol. 2007; 30: 737-743
        • Bonnet F.
        • Mercie P.
        • Morlat P.
        • et al.
        Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus.
        Lupus. 1999; 8: 244-247
        • Pittock S.J.
        • Weinshenker B.G.
        • Lucchinetti C.F.
        • Wingerchuk D.M.
        • Corboy J.R.
        • Lennon V.A.
        Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.
        Arch Neurol. 2006; 63: 964-968
        • Poppe A.Y.
        • Lapierre Y.
        • Melancon D.
        • et al.
        Neuromyelitis optica with hypothalamic involvement.
        Mult Scler. 2005; 11: 617-621
        • Vernant J.C.
        • Cabre P.
        • Smadja D.
        • et al.
        Recurrent optic neuromyelitis with endocrinopathies: a new syndrome.
        Neurology. 1997; 48: 58-64
        • Papais-Alvarenga R.M.
        • Carellos S.C.
        • Alvarenga M.P.
        • Holander C.
        • Bichara R.P.
        • Thuler L.C.
        Clinical course of optic neuritis in patients with relapsing neuromyelitis optica.
        Arch Ophthalmol. 2008; 126: 12-16
        • Misu T.
        • Fujihara K.
        • Itoyama Y.
        [Neuromyelitis optica and anti-aquaporin 4 antibody—an overview.
        Brain Nerve. 2008; 60: 527-537
        • Wu J.S.
        • Zhang M.N.
        • Carroll W.M.
        • Kermode A.G.
        Characterisation of the spectrum of demyelinating disease in Western Australia.
        J Neurol Neurosurg Psychiatry. 2008; 79: 1022-1026
        • Shibasaki H.
        • Okihiro M.M.
        • Kuroiwa Y.
        Multiple sclerosis among Orientals and Caucasians in Hawaii: a reappraisal.
        Neurology. 1978; 28: 113-118
        • Silber M.H.
        • Willcox P.A.
        • Bowen R.M.
        • Unger A.
        Neuromyelitis optica (Devic's syndrome) and pulmonary tuberculosis.
        Neurology. 1990; 40: 934-938
        • Mandler R.N.
        • Ahmed W.
        • Dencoff J.E.
        Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.
        Neurology. 1998; 51: 1219-1220
        • Minagar A.
        • Sheremata W.A.
        Treatment of Devic's disease with methotrexate and prednisone.
        Intl J MS Care. 2000; ([Serial online]): 2
        • Watanabe S.
        • Nakashima I.
        • Misu T.
        • et al.
        Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.
        Mult Scler. 2007; 13: 128-132
        • Watanabe S.
        • Misu T.
        • Miyazawa I.
        • et al.
        Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.
        Mult Scler. 2007; 13: 968-974
        • Cree B.A.
        • Lamb S.
        • Morgan K.
        • Chen A.
        • Waubant E.
        • Genain C.
        An open label study of the effects of rituximab in neuromyelitis optica.
        Neurology. 2005; 64: 1270-1272
        • Jacob A.
        • Weinshenker B.G.
        • Violich I.
        • et al.
        Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
        Arch Neurol. 2008; 65: 1443-1448
        • Weinstock-Guttman B.
        • Ramanathan M.
        • Lincoff N.
        • et al.
        Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
        Arch Neurol. 2006; 63: 957-963